364 related articles for article (PubMed ID: 9198203)
21. Clinical significance of expression of membrane type 1 matrix metalloproteinase and matrix metalloproteinase-2 in human head and neck squamous cell carcinoma.
Imanishi Y; Fujii M; Tokumaru Y; Tomita T; Kanke M; Kanzaki J; Kameyama K; Otani Y; Sato H
Hum Pathol; 2000 Aug; 31(8):895-904. PubMed ID: 10987249
[TBL] [Abstract][Full Text] [Related]
22. Sequence motifs of tissue inhibitor of metalloproteinases 2 (TIMP-2) determining progelatinase A (proMMP-2) binding and activation by membrane-type metalloproteinase 1 (MT1-MMP).
Worley JR; Thompkins PB; Lee MH; Hutton M; Soloway P; Edwards DR; Murphy G; Knäuper V
Biochem J; 2003 Jun; 372(Pt 3):799-809. PubMed ID: 12630911
[TBL] [Abstract][Full Text] [Related]
23. Identification and characterization of human MT5-MMP, a new membrane-bound activator of progelatinase a overexpressed in brain tumors.
Llano E; Pendás AM; Freije JP; Nakano A; Knäuper V; Murphy G; López-Otin C
Cancer Res; 1999 Jun; 59(11):2570-6. PubMed ID: 10363975
[TBL] [Abstract][Full Text] [Related]
24. Activation of progelatinase B (MMP-9) by gelatinase A (MMP-2).
Fridman R; Toth M; Peña D; Mobashery S
Cancer Res; 1995 Jun; 55(12):2548-55. PubMed ID: 7780967
[TBL] [Abstract][Full Text] [Related]
25. Expression and tissue localization of membrane-types 1, 2, and 3 matrix metalloproteinases in human urothelial carcinomas.
Kitagawa Y; Kunimi K; Ito H; Sato H; Uchibayashi T; Okada Y; Seiki M; Namiki M
J Urol; 1998 Oct; 160(4):1540-5. PubMed ID: 9751409
[TBL] [Abstract][Full Text] [Related]
26. Cell surface activation of progelatinase A (proMMP-2) and cell migration.
Nagase H
Cell Res; 1998 Sep; 8(3):179-86. PubMed ID: 9791731
[TBL] [Abstract][Full Text] [Related]
27. Activation of pro-MMP-2 mediated by MT1-MMP in human salivary gland carcinomas: possible regulation of pro-MMP-2 activation by TIMP-2.
Kayano K; Shimada T; Shinomiya T; Nakai S; Hisa Y; Aoki T; Seiki M; Okada Y
J Pathol; 2004 Apr; 202(4):403-11. PubMed ID: 15095267
[TBL] [Abstract][Full Text] [Related]
28. Membrane-type 1 matrix metalloproteinase-mediated progelatinase A activation in non-tumorigenic and tumorigenic human keratinocytes.
Baumann P; Zigrino P; Mauch C; Breitkreutz D; Nischt R
Br J Cancer; 2000 Nov; 83(10):1387-93. PubMed ID: 11044366
[TBL] [Abstract][Full Text] [Related]
29. Homophilic complex formation of MT1-MMP facilitates proMMP-2 activation on the cell surface and promotes tumor cell invasion.
Itoh Y; Takamura A; Ito N; Maru Y; Sato H; Suenaga N; Aoki T; Seiki M
EMBO J; 2001 Sep; 20(17):4782-93. PubMed ID: 11532942
[TBL] [Abstract][Full Text] [Related]
30. Progelatinase A activation during tumor cell invasion.
Stetler-Stevenson WG
Invasion Metastasis; 1994-1995; 14(1-6):259-68. PubMed ID: 7657518
[TBL] [Abstract][Full Text] [Related]
31. Expression of gelatinase A and its activator MT1-MMP in the inflammatory periprosthetic response to polyethylene.
Nawrocki B; Polette M; Burlet H; Birembaut P; Adnet JJ
J Bone Miner Res; 1999 Feb; 14(2):288-94. PubMed ID: 9933484
[TBL] [Abstract][Full Text] [Related]
32. Testican 2 abrogates inhibition of membrane-type matrix metalloproteinases by other testican family proteins.
Nakada M; Miyamori H; Yamashita J; Sato H
Cancer Res; 2003 Jun; 63(12):3364-9. PubMed ID: 12810672
[TBL] [Abstract][Full Text] [Related]
33. Plasmin activates pro-matrix metalloproteinase-2 with a membrane-type 1 matrix metalloproteinase-dependent mechanism.
Monea S; Lehti K; Keski-Oja J; Mignatti P
J Cell Physiol; 2002 Aug; 192(2):160-70. PubMed ID: 12115722
[TBL] [Abstract][Full Text] [Related]
34. Crystal structure of the complex formed by the membrane type 1-matrix metalloproteinase with the tissue inhibitor of metalloproteinases-2, the soluble progelatinase A receptor.
Fernandez-Catalan C; Bode W; Huber R; Turk D; Calvete JJ; Lichte A; Tschesche H; Maskos K
EMBO J; 1998 Sep; 17(17):5238-48. PubMed ID: 9724659
[TBL] [Abstract][Full Text] [Related]
35. Human membrane type-2 matrix metalloproteinase is defective in cell-associated activation of progelatinase A.
Miyamori H; Takino T; Seiki M; Sato H
Biochem Biophys Res Commun; 2000 Jan; 267(3):796-800. PubMed ID: 10673371
[TBL] [Abstract][Full Text] [Related]
36. Differential expression and origin of membrane-type 1 and 2 matrix metalloproteinases (MT-MMPs) in association with MMP2 activation in injured human livers.
Théret N; Musso O; L'Helgoualc'h A; Campion JP; Clément B
Am J Pathol; 1998 Sep; 153(3):945-54. PubMed ID: 9736043
[TBL] [Abstract][Full Text] [Related]
37. Matrix metalloproteinase-2 activation in human hepatic fibrosis regulation by cell-matrix interactions.
Préaux AM; Mallat A; Nhieu JT; D'Ortho MP; Hembry RM; Mavier P
Hepatology; 1999 Oct; 30(4):944-50. PubMed ID: 10498646
[TBL] [Abstract][Full Text] [Related]
38. Coordinate expression of membrane type-matrix metalloproteinases-2 and 3 (MT2-MMP and MT3-MMP) and matrix metalloproteinase-2 (MMP-2) in primary and metastatic melanoma cells.
Ohnishi Y; Tajima S; Ishibashi A
Eur J Dermatol; 2001; 11(5):420-3. PubMed ID: 11525948
[TBL] [Abstract][Full Text] [Related]
39. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression.
Hofmann UB; Westphal JR; Zendman AJ; Becker JC; Ruiter DJ; van Muijen GN
J Pathol; 2000 Jul; 191(3):245-56. PubMed ID: 10878545
[TBL] [Abstract][Full Text] [Related]
40. Increased expression of matrix metalloproteinase 7 and 9 and membrane type 1-matrix metalloproteinase in esophageal squamous cell carcinomas.
Ohashi K; Nemoto T; Nakamura K; Nemori R
Cancer; 2000 May; 88(10):2201-9. PubMed ID: 10820340
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
